Sengenics ImmuKyne Protein Array

Sengenics has launched the ImmuKyne protein array. The array is based on the company's KREX technology for discovering autoantibody biomarker signatures for predicting drug response and severe immune-related adverse events. The new product enables simultaneous screening of more than 300 immunomodulatory autoantigens comprising clinically significant protein classes that may be implicated in acute respiratory distress syndrome (ARDS), such as cytokines, chemokines, and interleukins. All proteins on ImmuKyne are full-length, correctly folded, and functional with both conformational and non-conformational epitopes preserved, which is critical as 90 percent of antibody binding sites are conformational in nature, the company said. The new tool is designed to further COVID-19 research by helping users understand whether autoantibodies play a role in progression to severe disease in COVID-19 patients.